Candesartan Improves Insulin Response in Hypertensive Patients
Author Information
Author(s): Suzuki Katsunori, Nakagawa Osamu, Aizawa Yoshifusa
Primary Institution: Saiseikai Niigata Second Hospital
Hypothesis
The study aimed to determine the effects of ARBs on insulin excretion by β-cells in hypertensive patients with impaired glucose tolerance.
Conclusion
Candesartan therapy improved early-phase insulin response in patients with impaired glucose tolerance and hypertension.
Supporting Evidence
- SBP decreased significantly from 144 mmHg to 125 mmHg in the candesartan group.
- The insulinogenic index significantly increased from 0.32 to 0.47 in the candesartan group.
- No significant changes in HOMA-R were identified in either group.
Takeaway
This study found that a medicine called candesartan helps the body make insulin better in people who have high blood pressure and trouble with sugar levels.
Methodology
Hypertensive patients with impaired glucose tolerance were randomly divided into two groups: one received candesartan and the other received dietary guidance only, with insulin response measured before and after three months.
Limitations
The study had a small sample size and a relatively short duration.
Participant Demographics
Participants were hypertensive patients with impaired glucose tolerance, average age around 55 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website